Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its target price cut by stock analysts at Piper Sandler from $12.00 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA – Research Report) and Century ...

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating ... has allowed Dr. Fossati’s lab to identify and ...

Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...